Teva's Copaxone boosted further as UK court rules against Mylan
This article was originally published in Scrip
Executive Summary
Following on from a recent similar ruling in the US courts, Mylan Laboratories got a knockback this week when the UK High Court of Justice issued a decision in favour of Teva Pharmaceutical Industries in a patent litigation proceeding brought by Mylan's UK subsidiary which had sought revocation of a patent for Copaxone (glatiramer acetate injection) which expires in May 2015, and a declaration that its generic of Copaxone would not infringe the patent.